These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16127074)

  • 21. D- and L-2',3'-didehydro-2',3'-dideoxy-3'-fluoro-carbocyclic nucleosides: synthesis, anti-HIV activity and mechanism of resistance.
    Wang J; Jin Y; Rapp KL; Schinazi RF; Chu CK
    J Med Chem; 2007 Apr; 50(8):1828-39. PubMed ID: 17373782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
    Lennerstrand J; Chu CK; Schinazi RF
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2078-84. PubMed ID: 17403997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.
    Nikolenko GN; Svarovskaia ES; Delviks KA; Pathak VK
    J Virol; 2004 Aug; 78(16):8761-70. PubMed ID: 15280484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
    Romano L; Venturi G; Bloor S; Harrigan R; Larder BA; Major JC; Zazzi M
    J Infect Dis; 2002 Apr; 185(7):898-904. PubMed ID: 11920313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes.
    Schinazi RF; Schlueter-Wirtz S; Stuyver L
    Antivir Chem Chemother; 2001; 12 Suppl 1():61-5. PubMed ID: 11594690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereoselective synthesis and antiviral activity of D-2',3'-didehydro-2',3'-dideoxy-2'-fluoro-4'-thionucleosides.
    Chong Y; Choo H; Choi Y; Mathew J; Schinazi RF; Chu CK
    J Med Chem; 2002 Oct; 45(22):4888-98. PubMed ID: 12383014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vitro selection and identification of HIV strain which is resistance to two new HIV-1 nonnucleoside reverse transcriptase inhibitors].
    Liu SY; Zhuang DM; Dong RH; Bai L; Li JY
    Yao Xue Xue Bao; 2010 Feb; 45(2):241-6. PubMed ID: 21351434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay.
    Ueno T; Mitsuya H
    Biochemistry; 1997 Feb; 36(5):1092-9. PubMed ID: 9033399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection and characterization of HIV-1 with a novel S68 deletion in reverse transcriptase.
    Schinazi RF; Massud I; Rapp KL; Cristiano M; Detorio MA; Stanton RA; Bennett MA; Kierlin-Duncan M; Lennerstrand J; Nettles JH
    Antimicrob Agents Chemother; 2011 May; 55(5):2054-60. PubMed ID: 21357304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
    Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
    Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
    Guillemont J; Pasquier E; Palandjian P; Vernier D; Gaurrand S; Lewi PJ; Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers MH; Arnold E; Das K; Pauwels R; Andries K; de Béthune MP; Bettens E; Hertogs K; Wigerinck P; Timmerman P; Janssen PA
    J Med Chem; 2005 Mar; 48(6):2072-9. PubMed ID: 15771449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways.
    Van Laethem K; Pannecouque C; Vandamme AM
    Infect Genet Evol; 2007 Sep; 7(5):600-3. PubMed ID: 17567542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro.
    Boyer PL; Gao HQ; Clark PK; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2001 Jul; 75(14):6321-8. PubMed ID: 11413298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates.
    Quan Y; Gu Z; Li X; Liang C; Parniak MA; Wainberg MA
    J Mol Biol; 1998 Mar; 277(2):237-47. PubMed ID: 9514745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 5'-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase.
    Wilson JE; Martin JL; Borroto-Esoda K; Hopkins S; Painter G; Liotta DC; Furman PA
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1720-2. PubMed ID: 7692813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
    Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
    Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase.
    Meteer JD; Koontz D; Asif G; Zhang HW; Detorio M; Solomon S; Coats SJ; Sluis-Cremer N; Schinazi RF; Mellors JW
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3758-64. PubMed ID: 21646480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.